Paul Gallant Takes GM Slot With 3D Bioprinting Innovators Organovo

Share this Article

1826458-poster-1826458-organovo-ceo-keith-murphy-is-refilling-the-cartridge-for-printing-human-organs-rotator

Keith Murphy, the CEO of bioprinting pioneers Organovo

Organovo Holdings, Inc. has made waves with their ability to deliver scientific and medical breakthroughs via 3D bioprinting technology.

The company’s 3D bioprinting methods enable the automated creation of living human tissues which mimic the form – and function – of human tissues within the body, and they’ve recently announced collaborations with L’Oreal to produce skin tissue which will be used for research and toxicity testing.organovo

They also inked a deals with Merck to print liver and kidney tissues which will be used to study drug toxicity and with the Yale School of Medicine to develop 3D organ tissues which will one day be used in surgical transplantation research.

Organovo now says that they’ve hired Paul Gallant, the former COO of DiscoveRx, a global scientific product and services company, as their General Manager of the company’s in vitro tissue service and product business.

Gallant’s experience includes more than 20 years of management and R&D work in the drug discovery industry.

According to Organovo, Gallant will be tasked with driving the success of the company’s toxicology contract research services business. He will work closely with the Organovo sales and marketing team alongside Michael Renard, and with the Research and Development team under Sharon Presnell.

“Paul has an impressive track record in creating business units and growing commercial operations to serve customers focused on research and development of innovative therapeutics. Paul’s experience in advancing new technology platforms in collaboration with pharmaceutical companies, contract research organizations and academic institutions will be invaluable as he develops and executes strategies for growing our business,” says Keith Murphy, the chairman and chief executive officer of Organovo.

loreal-organovoAt DiscoveRx, Gallant was responsible for the P&L results of that company’s largest business unit, drug discovery services. He also served as senior director at Ambit Pharmaceuticals, and led the development and commercialization efforts for the KINOMEscan platform, the world’s largest commercial kinase screening panel.

“Organovo offers a unique technology that has the potential to transform toxicology testing and drug development for the pharmaceutical industry, as well as develop long-range applications in organ replacement. I look forward to building Organovo’s customer base and developing and implementing strategies to advance Organovo’s products to realize the promise of 3D bioprinting,” Gallant said.

In addition to his other postings, Gallant also led R&D and service teams at Amgen, Inc., Millennium Pharmaceuticals, Inc., Cubist Pharmaceuticals Inc. and Massachusetts General Hospital.

Organovo has a number of products currently in development such as the exVive3D Human Kidney Tissue project, and that’s scheduled for released some time in late 2016. The company is also actively conducting research on specific tissues for use in direct surgical applications.

Organovo says that, as of mid-June, they have nearly four years worth of cash on hand for operations and no debt. They say the decision to raise an additional $40 million via an underwritten public offering will provide funds for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

What do you think about this announcement that Paul Gallant has been named as a new General Manager at Organovo. Let us know in the Paul Gallant forum thread on 3DPB.com.

Share this Article


Recent News

Appliance Maker Miele Offers 3D Printable Accessories on Thingiverse

New Facility for Bioengineering Research Opens in Los Angeles



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Featured

A Guide to Bioprinting: Understanding a Booming Industry

The success of bioprinting could become the key enabler that personalized medicine, tissue engineering, and regenerative medicine need to become a part of medical arsenals. Breakthroughs in bioprinting will enable...

Cell Culture Bioreactor for Tissue Engineering

Researchers from the US and Portugal are refining tissue engineering applications further, releasing the findings of their study in the recently published ‘A Multimodal Stimulation Cell Culture Bioreactor for Tissue...

3D Printing for Nerve Regeneration: Gelatin Methacrylate-Based Nerve Guidance Conduits

Chinese researchers delve deeply into tissue engineering, releasing the findings of their recent study in ‘3D printing of gelatin methacrylate-based nerve guidance conduits with multiple channels.’ While there have been...

3D Printing: Successful Scaffolds in Bone Regeneration

In ‘Comprehensive Review on Full Bone Regeneration through 3D Printing Approaches,’ the authors review new developments and solutions in tissue engineering for the formation of cells, as well as proposing...


Shop

View our broad assortment of in house and third party products.


Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our 3DPrint.com.

You have Successfully Subscribed!